{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:21:10Z","timestamp":1776093670870,"version":"3.50.1"},"reference-count":161,"publisher":"Bentham Science Publishers Ltd.","issue":"41","funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/QUI\/00100\/2013"],"award-info":[{"award-number":["UID\/QUI\/00100\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,1,8]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Transition metal complexes, of which the platinum(II) complex cisplatin is an example, have been used in medicine to treat cancer for more than 40 years. Although many successes have been achieved, there are problems associated with the use of these drugs, such as side effects and drug resistance. Converting them into prodrugs, to make them more inert, so that they can travel to the tumour site unchanged and release the drug in its active form only there, is a strategy which is the subject of much research nowadays. The new prodrugs may be activated and release the cytotoxic agent by differences in oxygen concentration or in pH, by the action of overexpressed enzymes, by differences in metabolic rates, etc., which characteristically distinguish cancer cells from normal ones, or even by the input of radiation, which can be visible light. Converting a metal complex into a prodrug may also be used to improve its pharmacological properties. In some cases, the metal complex is a carrier which transports the active drug as a ligand. Some platinum prodrugs have reached clinical trials. So far platinum, ruthenium and cobalt have been the most studied metals. This review presents the recent developments in this area, including the types of complexes used, the mechanisms of drug action and in some cases the techniques applied to monitor drug delivery to cells.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867326666181203141122","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T11:54:30Z","timestamp":1543838070000},"page":"7476-7519","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Transition Metal-Based Prodrugs for Anticancer Drug Delivery"],"prefix":"10.2174","volume":"26","author":[{"given":"Ana M.F.","family":"Phillips","sequence":"first","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Complexo I, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal"}]},{"given":"Armando J.L.","family":"Pombeiro","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Complexo I, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1021\/cr980419w","volume":"99","author":"Orvig C.","year":"1999","unstructured":"Orvig C.; Abrams M.J.; Medicinal inorganic chemistry: introduction. Chem Rev 1999,99(9),2201-2204","journal-title":"Chem Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"Johnstone T.C.","year":"2016","unstructured":"Johnstone T.C.; Suntharalingam K.; Lippard S.J.; The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 2016,116(5),3436-3486","journal-title":"Chem Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.coph.2012.04.006","volume":"12","author":"Lain\u00e9 A-L.","year":"2012","unstructured":"Lain\u00e9 A-L.; Passirani C.; Novel metal-based anticancer drugs: a new challenge in drug delivery. Curr Opin Pharmacol 2012,12(4),420-426","journal-title":"Curr Opin Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ejic.201600908","volume":"2017","author":"Zhang P.","year":"2017","unstructured":"Zhang P.; Sadler P.J.; Redox-active metal complexes for anticancer therapy. Eur J Inorg Chem 2017,2017(12),1541-1548","journal-title":"Eur J Inorg Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1039\/C4MT00069B","volume":"6","author":"Renfrew A.K.","year":"2014","unstructured":"Renfrew A.K.; Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. Metallomics 2014,6(8),1324-1335","journal-title":"Metallomics"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2013.0099","volume":"369","author":"Swietach P.","year":"2014","unstructured":"Swietach P.; Vaughan-Jones R.D.; Harris A.L.; Hulikova A.; The chemistry, physiology and pathology of pH in cancer. Philos Trans R Soc Lond B Biol Sci 2014,369(1638)","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fonc.2015.00115","volume":"5","author":"Wagner M.","year":"2015","unstructured":"Wagner M.; Wiig H.; Tumor interstitial fluid formation, characterization, and clinical implications. Front Oncol 2015,5,115","journal-title":"Front Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"Kelland L.","year":"2007","unstructured":"Kelland L.; The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007,7(8),573-584","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"14298","DOI":"10.1073\/pnas.162491399","volume":"99","author":"Ishida S.","year":"2002","unstructured":"Ishida S.; Lee J.; Thiele D.J.; Herskowitz I.; Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002,99(22),14298-14302","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.drudis.2009.09.003","volume":"14","author":"van Rijt S.H.","year":"2009","unstructured":"van Rijt S.H.; Sadler P.J.; Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today 2009,14(23-24),1089-1097","journal-title":"Drug Discov Today"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"Bruno P.M.","year":"2017","unstructured":"Bruno P.M.; Liu Y.; Park G.Y.; Murai J.; Koch C.E.; Eisen T.J.; Pritchard J.R.; Pommier Y.; Lippard S.J.; Hemann M.T.; A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 2017,23(4),461-471","journal-title":"Nat Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1039\/C7CS00195A","volume":"46","author":"Zeng L.","year":"2017","unstructured":"Zeng L.; Gupta P.; Chen Y.; Wang E.; Ji L.; Chao H.; Chen Z-S.; The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev 2017,46(19),5771-5804","journal-title":"Chem Soc Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jorganchem.2010.11.009","volume":"696","author":"Ang W.H.","year":"2011","unstructured":"Ang W.H.; Casini A.; Sava G.; Dyson P.J.; Organometallic ruthenium-based antitumor compounds with novel modes of action. J Organomet Chem 2011,696,989-998","journal-title":"J Organomet Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1021\/cr400460s","volume":"114","author":"Mjos K.D.","year":"2014","unstructured":"Mjos K.D.; Orvig C.; Metallodrugs in medicinal inorganic chemistry. Chem Rev 2014,114(8),4540-4563","journal-title":"Chem Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1021\/acschemneuro.7b00185","volume":"9","author":"Tonge P.J.","year":"2018","unstructured":"Tonge P.J.; Drug target kinetics in drug delivery. ACS Chem Neurosci 2018,9(1),29-39","journal-title":"ACS Chem Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.addr.2012.01.007","volume":"64","author":"Graf N.","year":"2012","unstructured":"Graf N.; Lippard S.J.; Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev 2012,64(11),993-1004","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1582-4934.2011.01258.x","volume":"15","author":"Carreau A.","year":"2011","unstructured":"Carreau A.; El Hafny-Rahbi B.; Matejuk A.; Grillon C.; Kieda C.; Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 2011,15(6),1239-1253","journal-title":"J Cell Mol Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5732\/cjc.012.10285","volume":"33","author":"Guise C.P.","year":"2014","unstructured":"Guise C.P.; Mowday A.M.; Ashoorzadeh A.; Yuan R.; Lin W-H.; Wu D-H.; Smaill J.B.; Patterson A.V.; Ding K.; Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer 2014,33(2),80-86","journal-title":"Chin J Cancer"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1083\/jcb.200402120","volume":"166","author":"\u00d8stergaard H.","year":"2004","unstructured":"\u00d8stergaard H.; Tachibana C.; Winther J.R.; Monitoring disulfide bond formation in the eukaryotic cytosol. J Cell Biol 2004,166(3),337-345","journal-title":"J Cell Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ica.2006.12.005","volume":"361","author":"Reisner E.","year":"2008","unstructured":"Reisner E.; Arion V.B.; Keppler B.K.; Pombeiro A.J.L.; Electron-transfer activated metal-based anticancer drugs. Inorg Chim Acta 2008,361(6),1569-1583","journal-title":"Inorg Chim Acta"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/9781118682975.ch10","author":"Simpson P.V.","year":"2014","unstructured":"Simpson P.V.; Schatzschneider U.; Release of Bioactive Molecules Using Metal Complexes. Inorganic Chemical Biology: Principles, Techniques and Applications 2014,309-339","journal-title":"Inorganic Chemical Biology: Principles, Techniques and Applications"},{"key":"ref=22","first-page":"6971","volume":"50","author":"Teicher B.A.","year":"1990","unstructured":"Teicher B.A.; Abrams M.J.; Rosbe K.W.; Herman T.S.; Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex. Cancer Res 1990,50(21),6971-6975","journal-title":"Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1039\/b707121c","author":"Hall M.D.","year":"2007","unstructured":"Hall M.D.; Failes T.W.; Yamamoto N.; Hambley T.W.; Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. Dalton Trans 2007(36),3983-3990","journal-title":"Dalton Trans"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1021\/jm00065a006","volume":"36","author":"Ware D.C.","year":"1993","unstructured":"Ware D.C.; Palmer B.D.; Wilson W.R.; Denny W.A.; Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem 1993,36(13),1839-1846","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1039\/b512322d","author":"Failes T.W.","year":"2006","unstructured":"Failes T.W.; Hambley T.W.; Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids. Dalton Trans 2006(15),1895-1901","journal-title":"Dalton Trans"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1002\/chem.200601137","volume":"13","author":"Failes T.W.","year":"2007","unstructured":"Failes T.W.; Cullinane C.; Diakos C.I.; Yamamoto N.; Lyons J.G.; Hambley T.W.; Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. Chemistry 2007,13(10),2974-2982","journal-title":"Chemistry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.bcp.2006.03.007","volume":"71","author":"Ahn G-O.","year":"2006","unstructured":"Ahn G-O.; Botting K.J.; Patterson A.V.; Ware D.C.; Tercel M.; Wilson W.R.; Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol 2006,71(12),1683-1694","journal-title":"Biochem Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.1021\/ja00097a006","volume":"116","author":"Boger D.L.","year":"1994","unstructured":"Boger D.L.; Yun W.; CBI-TMI: synthesis and evaluation of a key analog of the duocarmycins. Validation of a direct relationship between chemical solvolytic stability and cytotoxic potency and confirmation of the structural features responsible for the distinguishing behavior of enantiomeric pairs of agents. J Am Chem Soc 1994,116(18),7996-8006","journal-title":"J Am Chem Soc"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.1021\/jm9008746","volume":"52","author":"Milbank J.B.J.","year":"2009","unstructured":"Milbank J.B.J.; Stevenson R.J.; Ware D.C.; Chang J.Y.C.; Tercel M.; Ahn G-O.; Wilson W.R.; Denny W.A.; Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. J Med Chem 2009,52(21),6822-6834","journal-title":"J Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1667\/RR3229","volume":"162","author":"Ahn G.O.","year":"2004","unstructured":"Ahn G.O.; Ware D.C.; Denny W.A.; Wilson W.R.; Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat Res 2004,162(3),315-325","journal-title":"Radiat Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00775-008-0374-7","volume":"13","author":"Yamamoto N.","year":"2008","unstructured":"Yamamoto N.; Danos S.; Bonnitcha P.D.; Failes T.W.; New E.J.; Hambley T.W.; Cellular uptake and distribution of cobalt complexes of fluorescent ligands. J Biol Inorg Chem 2008,13(6),861-871","journal-title":"J Biol Inorg Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1016\/j.bmc.2011.06.076","volume":"19","author":"Lu G-L.","year":"2011","unstructured":"Lu G-L.; Stevenson R.J.; Chang J.Y-C.; Brothers P.J.; Ware D.C.; Wilson W.R.; Denny W.A.; Tercel M.; N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs. Bioorg Med Chem 2011,19(16),4861-4867","journal-title":"Bioorg Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"7688","DOI":"10.1021\/ic4006967","volume":"52","author":"Chang J.Y-C.","year":"2013","unstructured":"Chang J.Y-C.; Lu G-L.; Stevenson R.J.; Brothers P.J.; Clark G.R.; Botting K.J.; Ferry D.M.; Tercel M.; Wilson W.R.; Denny W.A.; Ware D.C.; Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs. Inorg Chem 2013,52(13),7688-7698","journal-title":"Inorg Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1039\/c3sc51530c","volume":"4","author":"Renfrew A.K.","year":"2013","unstructured":"Renfrew A.K.; Bryce N.S.; Hambley T.W.; Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study. Chem Sci (Camb) 2013,4,3731-3739","journal-title":"Chem Sci (Camb)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jinorgbio.2016.01.024","volume":"157","author":"Pires B.M.","year":"2016","unstructured":"Pires B.M.; Giacomin L.C.; Castro F.A.V.; Cavalcanti, Ados.S.; Pereira, M.D.; Bortoluzzi, A.J.; Faria, R.B.; Scarpellini, M. Azido- and chlorido-cobalt complex as carrier-prototypes for antitumoral prodrugs. J Inorg Biochem 2016,157,104-113","journal-title":"J Inorg Biochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"12930","DOI":"10.1002\/anie.201403936","volume":"53","author":"Karnthaler-Benbakka C.","year":"2014","unstructured":"Karnthaler-Benbakka C.; Groza D.; Kryeziu K.; Pichler V.; Roller A.; Berger W.; Heffeter P.; Kowol C.R.; Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation. Angew Chem Int Ed Engl 2014,53(47),12930-12935","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1039\/C6DT04443C","volume":"46","author":"Rossier J.","year":"2017","unstructured":"Rossier J.; Hauser D.; Kottelat E.; Rothen-Rutishauser B.; Zobi F.; Organometallic cobalamin anticancer derivatives for targeted prodrug delivery via transcobalamin-mediated uptake. Dalton Trans 2017,46(7),2159-2164","journal-title":"Dalton Trans"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1128\/JB.182.15.4304-4309.2000","volume":"182","author":"Fonseca M.V.","year":"2000","unstructured":"Fonseca M.V.; Escalante-Semerena J.C.; Reduction of Cob(III)alamin to Cob(II)alamin in Salmonella enterica serovar typhimurium LT2. J Bacteriol 2000,182(15),4304-4309","journal-title":"J Bacteriol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00775-007-0329-4","volume":"13","author":"Ruiz-S\u00e1nchez P.","year":"2008","unstructured":"Ruiz-S\u00e1nchez P.; Mundwiler S.; Spingler B.; Buan N.R.; Escalante-Semerena J.C.; Alberto R.; Syntheses and characterization of vitamin B12-Pt(II) conjugates and their adenosylation in an enzymatic assay. J Biol Inorg Chem 2008,13(3),335-347","journal-title":"J Biol Inorg Chem"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.2012.0519","volume":"371","author":"Smith N.A.","year":"2013","unstructured":"Smith N.A.; Sadler P.J.; Photoactivatable metal complexes: from theory to applications in biotechnology and medicine. Philos Trans- Royal Soc, Math Phys Eng Sci 2013,371(1995)","journal-title":"Philos Trans- Royal Soc, Math Phys Eng Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/156802612799078973","volume":"12","author":"Chiang L.","year":"2012","unstructured":"Chiang L.; Jones M.R.; Ferreira C.L.; Storr T.; Multifunctional ligands in medicinal inorganic chemistry--current trends and future directions. Curr Top Med Chem 2012,12(3),122-144","journal-title":"Curr Top Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1039\/C5DT03919C","volume":"45","author":"Allardyce C.S.","year":"2016","unstructured":"Allardyce C.S.; Dyson P.J.; Metal-based drugs that break the rules. Dalton Trans 2016,45(8),3201-3209","journal-title":"Dalton Trans"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1367-5931(03)00081-4","volume":"7","author":"Zhang C.X.","year":"2003","unstructured":"Zhang C.X.; Lippard S.J.; New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003,7(4),481-489","journal-title":"Curr Opin Chem Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trac.2017.09.023","volume":"104","author":"Holtkamp H.U.","year":"2018","unstructured":"Holtkamp H.U.; Hartinger C.G.; Advanced metallomics methods in anticancer metallodrug mode of action studies. Trends Analyt Chem 2018,104,110-117","journal-title":"Trends Analyt Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1021\/ja0278943","volume":"125","author":"Zayat L.","year":"2003","unstructured":"Zayat L.; Calero C.; Albor\u00e9s P.; Baraldo L.; Etchenique R.; A new strategy for neurochemical photodelivery: metal-ligand heterolytic cleavage. J Am Chem Soc 2003,125(4),882-883","journal-title":"J Am Chem Soc"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1039\/c3pp25248e","volume":"12","author":"Filevich O.","year":"2013","unstructured":"Filevich O.; Etchenique R.; RuBiGABA-2: a hydrophilic caged GABA with long wavelength sensitivity. Photochem Photobiol Sci 2013,12(9),1565-1570","journal-title":"Photochem Photobiol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"9213","DOI":"10.1021\/ic201615u","volume":"50","author":"Garner R.N.","year":"2011","unstructured":"Garner R.N.; Gallucci J.C.; Dunbar K.R.; Turro C.; [Ru(bpy)2(5-cyanouracil)2]2+ as a potential light-activated dual-action therapeutic agent. Inorg Chem 2011,50(19),9213-9215","journal-title":"Inorg Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1021\/ja806860w","volume":"131","author":"Liu Y.","year":"2009","unstructured":"Liu Y.; Turner D.B.; Singh T.N.; Angeles-Boza A.M.; Chouai A.; Dunbar K.R.; Turro C.; Ultrafast ligand exchange: detection of a pentacoordinate Ru(II) intermediate and product formation. J Am Chem Soc 2009,131(1),26-27","journal-title":"J Am Chem Soc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1021\/ic00178a028","volume":"23","author":"Pinnick D.V.","year":"1984","unstructured":"Pinnick D.V.; Durham B.; Photosubstitution reactions of Ru(bpy)2XYn+ complexes. Inorg Chem 1984,23(10),1440-1445","journal-title":"Inorg Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.ica.2010.04.014","volume":"363","author":"Cruz A.J.","year":"2010","unstructured":"Cruz A.J.; Kirgan R.; Siam K.; Heiland P.; Rillema D.P.; Photochemical and photophysical properties of ruthenium(II) bis-bipyridine bis-nitrile complexes. Photolability Inorg Chim Acta 2010,363(11),2496-2505","journal-title":"Photolability Inorg Chim Acta"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"17164","DOI":"10.1021\/ja208084s","volume":"133","author":"Respondek T.","year":"2011","unstructured":"Respondek T.; Garner R.N.; Herroon M.K.; Podgorski I.; Turro C.; Kodanko J.J.; Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with Ru((bpy). J Am Chem Soc 2011,133(43),17164-17167","journal-title":"J Am Chem Soc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2007.10.011","volume":"29","author":"Palermo C.","year":"2008","unstructured":"Palermo C.; Joyce J.A.; Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008,29(1),22-28","journal-title":"Trends Pharmacol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"11274","DOI":"10.1021\/ja4045604","volume":"135","author":"Sgambellone M.A.","year":"2013","unstructured":"Sgambellone M.A.; David A.; Garner R.N.; Dunbar K.R.; Turro C.; Cellular toxicity induced by the photorelease of a caged bioactive molecule: design of a potential dual-action Ru(II) complex. J Am Chem Soc 2013,135(30),11274-11282","journal-title":"J Am Chem Soc"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1021\/ic500299s","volume":"53","author":"Sharma R.","year":"2014","unstructured":"Sharma R.; Knoll J.D.; Martin P.D.; Podgorski I.; Turro C.; Kodanko J.J.; Ruthenium tris(2-pyridylmethyl)amine as an effective photocaging group for nitriles. Inorg Chem 2014,53(7),3272-3274","journal-title":"Inorg Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.bmcl.2006.01.104","volume":"16","author":"Altmann E.","year":"2006","unstructured":"Altmann E.; Aichholz R.; Betschart C.; Buhl T.; Green J.; Lattmann R.; Missbach M.; Dipeptide nitrile inhibitors of cathepsin K. Bioorg Med Chem Lett 2006,16(9),2549-2554","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.1021\/ic5017164","volume":"53","author":"Hidayatullah A.N.","year":"2014","unstructured":"Hidayatullah A.N.; Wachter E.; Heidary D.K.; Parkin S.; Glazer E.C.; Photoactive Ru(II) complexes with dioxinophenanthroline ligands are potent cytotoxic agents. Inorg Chem 2014,53(19),10030-10032","journal-title":"Inorg Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1002\/anie.201309576","volume":"53","author":"Joshi T.","year":"2014","unstructured":"Joshi T.; Pierroz V.; Mari C.; Gemperle L.; Ferrari S.; Gasser G.; A bis(dipyridophenazine)(2-(2-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) complex with anticancer action upon photodeprotection. Angew Chem Int Ed Engl 2014,53(11),2960-2963","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1002\/ejic.201500602","volume":"2015","author":"Mari C.","year":"2015","unstructured":"Mari C.; Pierroz V.; Leonidova A.; Ferrari S.; Gasser G.; Towards selective light-activated RuII-based prodrug candidates. Eur J Inorg Chem 2015,2015(23),3879-3891","journal-title":"Eur J Inorg Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1039\/c2cc30819c","volume":"48","author":"Dcona M.M.","year":"2012","unstructured":"Dcona M.M.; Mitra D.; Goehe R.W.; Gewirtz D.A.; Lebman D.A.; Hartman M.C.T.; Photocaged permeability: a new strategy for controlled drug release. Chem Commun (Camb) 2012,48(39),4755-4757","journal-title":"Chem Commun (Camb)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/ejoc.200700972","volume":"2008","author":"Lin W.","year":"2008","unstructured":"Lin W.; Peng D.; Wang B.; Long L.; Guo C.; Yuan J.; A model for light-triggered anticancer prodrugs based on an o-nitrobenzyl photolabile group. Eur J Org Chem 2008,2008(5),793-796","journal-title":"Eur J Org Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jinorgbio.2013.10.008","volume":"130","author":"Hufziger K.T.","year":"2014","unstructured":"Hufziger K.T.; Thowfeik F.S.; Charboneau D.J.; Nieto I.; Dougherty W.G.; Kassel W.S.; Dudley T.J.; Merino E.J.; Papish E.T.; Paul J.J.; Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release. J Inorg Biochem 2014,130,103-111","journal-title":"J Inorg Biochem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1021\/acs.inorgchem.7b01065","volume":"56","author":"Qu F.","year":"2017","unstructured":"Qu F.; Park S.; Martinez K.; Gray J.L.; Thowfeik F.S.; Lundeen J.A.; Kuhn A.E.; Charboneau D.J.; Gerlach D.L.; Lockart M.M.; Law J.A.; Jernigan K.L.; Chambers N.; Zeller M.; Piro N.A.; Kassel W.S.; Schmehl R.H.; Paul J.J.; Merino E.J.; Kim Y.; Papish E.T.; Ruthenium complexes are pH-activated metallo prodrugs (pHAMPs) with light-triggered selective toxicity toward cancer cells. Inorg Chem 2017,56(13),7519-7532","journal-title":"Inorg Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"14038","DOI":"10.1039\/C5CC05172J","volume":"51","author":"Karaoun N.","year":"2015","unstructured":"Karaoun N.; Renfrew A.K.; A luminescent ruthenium(II) complex for light-triggered drug release and live cell imaging. Chem Commun (Camb) 2015,51(74),14038-14041","journal-title":"Chem Commun (Camb)"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"9924","DOI":"10.1002\/chem.201101541","volume":"17","author":"Goldbach R.E.","year":"2011","unstructured":"Goldbach R.E.; Rodriguez-Garcia I.; van Lenthe J.H.; Siegler M.A.; Bonnet S.; N-acetylmethionine and biotin as photocleavable protective groups for ruthenium polypyridyl complexes. Chemistry 2011,17(36),9924-9929","journal-title":"Chemistry"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1021\/ic00004a013","volume":"30","author":"Hecker C.R.","year":"1991","unstructured":"Hecker C.R.; Fanwick P.E.; McMillin D.R.; Evidence for dissociative photosubstitution reactions of [Ru(trpy)(bpy)(NCCH)]. Crystal and molecular structure of [Ru(trpy)(bpy)(py)](PF)\u2022(CH)CO. Inorg Chem 1991,30(4),659-666","journal-title":"Inorg Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jinorgbio.2015.05.010","volume":"150","author":"van Rixel V.H.S.","year":"2015","unstructured":"van Rixel V.H.S.; Busemann A.; G\u00f6ttle A.J.; Bonnet S.; Preparation, stability, and photoreactivity of thiolato ruthenium polypyridyl complexes: Can cysteine derivatives protect ruthenium-based anticancer complexes? J Inorg Biochem 2015,150,174-181","journal-title":"J Inorg Biochem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"18484","DOI":"10.1002\/chem.201603066","volume":"22","author":"Lameijer L.N.","year":"2016","unstructured":"Lameijer L.N.; Hopkins S.L.; Brev\u00e9 T.G.; Askes S.H.C.; Bonnet S.; D- versus L-glucose conjugation: mitochondrial targeting of a light-activated dual-mode-of-action ruthenium-based anticancer prodrug. Chemistry 2016,22(51),18484-18491","journal-title":"Chemistry"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1039\/C6DT04405K","volume":"46","author":"Zamora A.","year":"2017","unstructured":"Zamora A.; Denning C.A.; Heidary D.K.; Wachter E.; Nease L.A.; Ruiz J.; Glazer E.C.; Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage. Dalton Trans 2017,46(7),2165-2173","journal-title":"Dalton Trans"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1535-7163.363.3.3","volume":"3","author":"McFadyen M.C.E.","year":"2004","unstructured":"McFadyen M.C.E.; Melvin W.T.; Murray G.I.; Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004,3(3),363-371","journal-title":"Mol Cancer Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cbi.2006.06.008","volume":"163","author":"Omura T.","year":"2006","unstructured":"Omura T.; Mitochondrial P450s. Chem Biol Interact 2006,163(1-2),86-93","journal-title":"Chem Biol Interact"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1016\/j.bmc.2007.05.046","volume":"15","author":"Bruno R.D.","year":"2007","unstructured":"Bruno R.D.; Njar V.C.O.; Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 2007,15(15),5047-5060","journal-title":"Bioorg Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1022308429992","volume":"5","author":"Nieman L.K.","year":"2002","unstructured":"Nieman L.K.; Medical therapy of Cushing\u2019s disease. Pituitary 2002,5(2),77-82","journal-title":"Pituitary"},{"key":"ref=73","first-page":"391","volume":"76","author":"Lynch T.","year":"2007","unstructured":"Lynch T.; Price A.; The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007,76(3),391-396","journal-title":"Am Fam Physician"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/ejic.201601450","volume":"2017","author":"Havrylyuk D.","year":"2017","unstructured":"Havrylyuk D.; Heidary D.K.; Nease L.; Parkin S.; Glazer E.C.; Photochemical properties and structure\u2013activity relationships of RuII complexes with pyridylbenzazole ligands as promising anticancer agents. Eur J Inorg Chem 2017,2017(12),1687-1694","journal-title":"Eur J Inorg Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jinorgbio.2017.11.018","volume":"179","author":"Wei J.","year":"2018","unstructured":"Wei J.; Renfrew A.K.; Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent. J Inorg Biochem 2018,179,146-153","journal-title":"J Inorg Biochem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1039\/C6DT01414C","volume":"45","author":"Gibson D.","year":"2016","unstructured":"Gibson D.; Platinum(iv) anticancer prodrugs - hypotheses and facts. Dalton Trans 2016,45(33),12983-12991","journal-title":"Dalton Trans"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ejic.201601278","volume":"2017","author":"Kenny R.G.","year":"2017","unstructured":"Kenny R.G.; Chuah S.W.; Crawford A.; Marmion C.J.; Platinum(IV) prodrugs - a step closer to Ehrlich\u2019s vision? Eur J Inorg Chem 2017,2017(12),1596-1612","journal-title":"Eur J Inorg Chem"},{"key":"ref=78","first-page":"1402","volume":"49","author":"Gibbons G.R.","year":"1989","unstructured":"Gibbons G.R.; Wyrick S.; Chaney S.G.; Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexan-eplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res 1989,49(6),1402-1407","journal-title":"Cancer Res"},{"key":"ref=79","first-page":"3533","volume":"48","author":"Pendyala L.","year":"1988","unstructured":"Pendyala L.; Cowens J.W.; Chheda G.B.; Dutta S.P.; Creaven P.J.; Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res 1988,48(12),3533-3536","journal-title":"Cancer Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF00685722","volume":"27","author":"Pendyala L.","year":"1990","unstructured":"Pendyala L.; Arakali A.V.; Sansone P.; Cowens J.W.; Creaven P.J.; DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II). Cancer Chemother Pharmacol 1990,27(3),248-250","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=81","first-page":"2581","volume":"53","author":"Kelland L.R.","year":"1993","unstructured":"Kelland L.R.; Abel G.; McKeage M.J.; Jones M.; Goddard P.M.; Valenti M.; Murrer B.A.; Harrap K.R.; Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993,53(11),2581-2586","journal-title":"Cancer Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1517\/13543780903362437","volume":"18","author":"Bhargava A.","year":"2009","unstructured":"Bhargava A.; Vaishampayan U.N.; Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs 2009,18(11),1787-1797","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1517\/13543784.9.6.1373","volume":"9","author":"Kelland L.R.","year":"2000","unstructured":"Kelland L.R.; An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000,9(6),1373-1382","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=84","first-page":"4881","volume":"56","author":"Fink D.","year":"1996","unstructured":"Fink D.; Nebel S.; Aebi S.; Zheng H.; Cenni B.; Nehm\u00e9 A.; Christen R.D.; Howell S.B.; The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996,56(21),4881-4886","journal-title":"Cancer Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s002800050464","volume":"38","author":"Raynaud F.I.","year":"1996","unstructured":"Raynaud F.I.; Mistry P.; Donaghue A.; Poon G.K.; Kelland L.R.; Barnard C.F.J.; Murrer B.A.; Harrap K.R.; Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996,38(2),155-162","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0010-8545(02)00026-7","volume":"232","author":"Hall M.D.","year":"2002","unstructured":"Hall M.D.; Hambley T.W.; Platinum(IV) antitumour compounds: their bioinorganic chemistry. Coord Chem Rev 2002,232(1-2),49-67","journal-title":"Coord Chem Rev"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1021\/jm0506468","volume":"48","author":"Ang W.H.","year":"2005","unstructured":"Ang W.H.; Pilet S.; Scopelliti R.; Bussy F.; Juillerat-Jeanneret L.; Dyson P.J.; Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J Med Chem 2005,48(25),8060-8069","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.1021\/jm300580y","volume":"55","author":"Chin C.F.","year":"2012","unstructured":"Chin C.F.; Tian Q.; Setyawati M.I.; Fang W.; Tan E.S.Q.; Leong D.T.T.; Ang W.H.; Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation. J Med Chem 2012,55(17),7571-7582","journal-title":"J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jinorgbio.2015.08.018","volume":"153","author":"H\u00f6fer D.","year":"2015","unstructured":"H\u00f6fer D.; Varbanov H.P.; Legin A.; Jakupec M.A.; Roller A.; Galanski M.; Keppler B.K.; Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy. J Inorg Biochem 2015,153,259-271","journal-title":"J Inorg Biochem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1021\/ic971047x","volume":"37","author":"Choi S.","year":"1998","unstructured":"Choi S.; Filotto C.; Bisanzo M.; Delaney S.; Lagasee D.; Whitworth J.L.; Jusko A.; Li C.; Wood N.A.; Willingham J.; Schwenker A.; Spaulding K.; Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 1998,37(10),2500-2504","journal-title":"Inorg Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"14404","DOI":"10.1039\/c2dt31366a","volume":"41","author":"Varbanov H.P.","year":"2012","unstructured":"Varbanov H.P.; Valiahdi S.M.; Kowol C.R.; Jakupec M.A.; Galanski M.; Keppler B.K.; Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. Dalton Trans 2012,41(47),14404-14415","journal-title":"Dalton Trans"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1039\/C1CC16647F","volume":"48","author":"Zhang J.Z.","year":"2012","unstructured":"Zhang J.Z.; Wexselblatt E.; Hambley T.W.; Gibson D.; Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. Chem Commun (Camb) 2012,48(6),847-849","journal-title":"Chem Commun (Camb)"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"8757","DOI":"10.1021\/jm401218n","volume":"56","author":"Chen C.K.J.","year":"2013","unstructured":"Chen C.K.J.; Zhang J.Z.; Aitken J.B.; Hambley T.W.; Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells. J Med Chem 2013,56(21),8757-8764","journal-title":"J Med Chem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jinorgbio.2015.11.028","volume":"160","author":"Margiotta N.","year":"2016","unstructured":"Margiotta N.; Savino S.; Marzano C.; Pacifico C.; Hoeschele J.D.; Gandin V.; Natile G.; Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands. J Inorg Biochem 2016,160,85-93","journal-title":"J Inorg Biochem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"29367","DOI":"10.1038\/srep29367","volume":"6","author":"Tolan D.","unstructured":"Tolan D.; Gandin V.; Morrison L.; El-Nahas A.; Marzano C.; Montagner D.; Erxleben A.; Oxidative stress induced by Pt(IV) pro-drugs based on the cisplatin scaffold and indole carboxylic acids in axial position. Nature Scientific Reports ,6,29367","journal-title":"Nature Scientific Reports"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2006.08.015","volume":"549","author":"Barbara C.","year":"2006","unstructured":"Barbara C.; Orlandi P.; Bocci G.; Fioravanti A.; Di Paolo A.; Natale G.; Del Tacca M.; Danesi R.; In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. Eur J Pharmacol 2006,549(1-3),27-34","journal-title":"Eur J Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"20743","DOI":"10.1073\/pnas.0707742105","volume":"104","author":"Mackay F.S.","year":"2007","unstructured":"Mackay F.S.; Woods J.A.; Heringov\u00e1 P.; Kasp\u00e1rkov\u00e1 J.; Pizarro A.M.; Moggach S.A.; Parsons S.; Brabec V.; Sadler P.J.; A potent cytotoxic photoactivated platinum complex. Proc Natl Acad Sci USA 2007,104(52),20743-20748","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1002\/chem.201300374","volume":"19","author":"Zhao Y.","year":"2013","unstructured":"Zhao Y.; Woods J.A.; Farrer N.J.; Robinson K.S.; Pracharova J.; Kasparkova J.; Novakova O.; Li H.; Salassa L.; Pizarro A.M.; Clarkson G.J.; Song L.; Brabec V.; Sadler P.J.; Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts. Chemistry 2013,19(29),9578-9591","journal-title":"Chemistry"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/bc070031k","volume":"19","author":"Mukhopadhyay S.","year":"2008","unstructured":"Mukhopadhyay S.; Barn\u00e9s C.M.; Haskel A.; Short S.M.; Barnes K.R.; Lippard S.J.; Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem 2008,19(1),39-49","journal-title":"Bioconjug Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.7512751","volume":"264","author":"Brooks P.C.","year":"1994","unstructured":"Brooks P.C.; Clark R.A.F.; Cheresh D.A.; Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994,264(5158),569-571","journal-title":"Science"},{"key":"ref=101","first-page":"722","volume":"60","author":"Pasqualini R.","year":"2000","unstructured":"Pasqualini R.; Koivunen E.; Kain R.; Lahdenranta J.; Sakamoto M.; Stryhn A.; Ashmun R.A.; Shapiro L.H.; Arap W.; Ruoslahti E.; Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000,60(3),722-727","journal-title":"Cancer Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc724","volume":"2","author":"Ruoslahti E.","year":"2002","unstructured":"Ruoslahti E.; Specialization of tumour vasculature. Nat Rev Cancer 2002,2(2),83-90","journal-title":"Nat Rev Cancer"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/blood-2008-04-150862","volume":"112","author":"Corti A.","year":"2008","unstructured":"Corti A.; Curnis F.; Arap W.; Pasqualini R.; The neovasculature homing motif NGR: more than meets the eye. Blood 2008,112(7),2628-2635","journal-title":"Blood"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1021\/ja9603721","volume":"118","author":"Haubner R.","year":"1996","unstructured":"Haubner R.; Gratias R.; Diefenbach B.; Goodman S.L.; Jonczyk A.; Kessler H.; Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin \u03b1\u03b2 antagonists. J Am Chem Soc 1996,118(32),7461-7472","journal-title":"J Am Chem Soc"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/anie.199713741","volume":"36","author":"Haubner R.","year":"1997","unstructured":"Haubner R.; Finsinger D.; Kessler H.; Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the \u03b1\u03b2 integrin for a new cancer therapy. Angew Chem Int Ed Engl 1997,36(13-14),1374-1389","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1002\/chem.201701192","volume":"23","author":"Reshetnikov V.","year":"2017","unstructured":"Reshetnikov V.; Daum S.; Mokhir A.; Cancer-specific, intracellular, reductive activation of anticancer PtIV prodrugs. Chemistry 2017,23(24),5678-5681","journal-title":"Chemistry"},{"key":"ref=107","first-page":"794","volume":"51","author":"Szatrowski T.P.","year":"1991","unstructured":"Szatrowski T.P.; Nathan C.F.; Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991,51(3),794-798","journal-title":"Cancer Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"9971","DOI":"10.1039\/C7CC05311H","volume":"53","author":"Muhammad N.","year":"2017","unstructured":"Muhammad N.; Sadia N.; Zhu C.; Luo C.; Guo Z.; Wang X.; Biotin-tagged platinum(iv) complexes as targeted cytostatic agents against breast cancer cells. Chem Commun (Camb) 2017,53(72),9971-9974","journal-title":"Chem Commun (Camb)"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1021\/bc9005656","volume":"21","author":"Chen S.","year":"2010","unstructured":"Chen S.; Zhao X.; Chen J.; Chen J.; Kuznetsova L.; Wong S.S.; Ojima I.; Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem 2010,21(5),979-987","journal-title":"Bioconjug Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.chembiol.2004.03.024","volume":"11","author":"Barnes K.R.","year":"2004","unstructured":"Barnes K.R.; Kutikov A.; Lippard S.J.; Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 2004,11(4),557-564","journal-title":"Chem Biol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"22199","DOI":"10.1073\/pnas.0912276106","volume":"106","author":"Dhar S.","year":"2009","unstructured":"Dhar S.; Lippard S.J.; Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci USA 2009,106(52),22199-22204","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0091270003254637","volume":"43","author":"Stacpoole P.W.","year":"2003","unstructured":"Stacpoole P.W.; Nagaraja N.V.; Hutson A.D.; Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003,43(7),683-691","journal-title":"J Clin Pharmacol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","volume":"11","author":"Bonnet S.","year":"2007","unstructured":"Bonnet S.; Archer S.L.; Allalunis-Turner J.; Haromy A.; Beaulieu C.; Thompson R.; Lee C.T.; Lopaschuk G.D.; Puttagunta L.; Bonnet S.; Harry G.; Hashimoto K.; Porter C.J.; Andrade M.A.; Thebaud B.; Michelakis E.D.; A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007,11(1),37-51","journal-title":"Cancer Cell"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1021\/mp200571k","volume":"9","author":"Xue X.","year":"2012","unstructured":"Xue X.; You S.; Zhang Q.; Wu Y.; Zou G-Z.; Wang P.C.; Zhao Y.L.; Xu Y.; Jia L.; Zhang X.; Liang X-J.; Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Mol Pharm 2012,9(3),634-644","journal-title":"Mol Pharm"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1002\/anie.201300640","volume":"52","author":"Wexselblatt E.","year":"2013","unstructured":"Wexselblatt E.; Yavin E.; Gibson D.; Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions. Angew Chem Int Ed Engl 2013,52(23),6059-6062","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/ja0432618","volume":"127","author":"Ang W.H.","year":"2005","unstructured":"Ang W.H.; Khalaila I.; Allardyce C.S.; Juillerat-Jeanneret L.; Dyson P.J.; Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc 2005,127(5),1382-1383","journal-title":"J Am Chem Soc"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0009-2797(97)00169-5","volume":"111-112","author":"Niitsu Y.","year":"1998","unstructured":"Niitsu Y.; Takahashi Y.; Ban N.; Takayama T.; Saito T.; Katahira T.; Umetsu Y.; Nakajima T.; Ohi M.; Kuga T.; Sakamaki S.; Matsunaga T.; Hirayama Y.; Kuroda H.; Homma H.; Kato J.; Kogawa K.; A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem Biol Interact 1998,111-112,325-332","journal-title":"Chem Biol Interact"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1021\/mp200597r","volume":"9","author":"Yang J.","year":"2012","unstructured":"Yang J.; Sun X.; Mao W.; Sui M.; Tang J.; Shen Y.; Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy. Mol Pharm 2012,9(10),2793-2800","journal-title":"Mol Pharm"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"Duenas-Gonzalez A.","year":"2008","unstructured":"Duenas-Gonzalez A.; Candelaria M.; Perez-Plascencia C.; Perez-Cardenas E.; de la Cruz-Hernandez E.; Herrera L.A.; Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008,34(3),206-222","journal-title":"Cancer Treat Rev"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp200597r","volume":"9","author":"Venkataramani V.","year":"2012","unstructured":"Venkataramani V.; Rossner C.; Iffland L.; Schweyer S.; Tamboli I.Y.; Walter J.; Wirths O.; Bayer T.A.; Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-molecular pharmaceutics. Mol Pharm 2012,9,2793-2800","journal-title":"Mol Pharm"},{"key":"ref=121","author":"Patrick G.L.","year":"2009","unstructured":"Patrick G.L.; An Introduction to Medicinal Chemistry 2009","journal-title":"An Introduction to Medicinal Chemistry"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"14478","DOI":"10.1002\/anie.201506533","volume":"54","author":"Kasparkova J.","year":"2015","unstructured":"Kasparkova J.; Kostrhunova H.; Novakova O.; K\u0159ikavov\u00e1 R.; Van\u010do J.; Tr\u00e1vn\u00ed\u010dek Z.; Brabec V.; A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases. Angew Chem Int Ed Engl 2015,54(48),14478-14482","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejmech.2017.09.074","volume":"141","author":"Xu Z.","year":"2017","unstructured":"Xu Z.; Hu W.; Wang Z.; Gou S.; Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1. Eur J Med Chem 2017,141,211-220","journal-title":"Eur J Med Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"Ashworth A.","year":"2008","unstructured":"Ashworth A.; A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008,26(22),3785-3790","journal-title":"J Clin Oncol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.bmcl.2009.12.042","volume":"20","author":"Gandhi V.B.","year":"2010","unstructured":"Gandhi V.B.; Luo Y.; Liu X.; Shi Y.; Klinghofer V.; Johnson E.F.; Park C.; Giranda V.L.; Penning T.D.; Zhu G.D.; Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem Lett 2010,20(3),1023-1026","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1021\/acs.jmedchem.5b00099","volume":"58","author":"Tang C.","year":"2015","unstructured":"Tang C.; Li C.; Zhang S.; Hu Z.; Wu J.; Dong C.; Huang J.; Zhou H.B.; Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer. J Med Chem 2015,58(11),4550-4572","journal-title":"J Med Chem"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"14174","DOI":"10.1039\/C7DT02928D","volume":"46","author":"Gabano E.","year":"2017","unstructured":"Gabano E.; Ravera M.; Zanellato I.; Tinello S.; Gallina A.; Rangone B.; Gandin V.; Marzano C.; Bottone M.G.; Osella D.; An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Trans 2017,46(41),14174-14185","journal-title":"Dalton Trans"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neulet.2010.04.013","volume":"476","author":"Leng Y.","year":"2010","unstructured":"Leng Y.; Marinova Z.; Reis-Fernandes M.A.; Nau H.; Chuang D-M.; Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett 2010,476(3),127-132","journal-title":"Neurosci Lett"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1021\/acs.bioconjchem.7b00117","volume":"28","author":"Huang X.","year":"2017","unstructured":"Huang X.; Huang R.; Gou S.; Wang Z.; Wang H.; Anticancer platinum(IV) prodrugs containing monoaminophosphonate ester as a targeting group inhibit matrix metalloproteinases and reverse multidrug resistance. Bioconjug Chem 2017,28(4),1305-1323","journal-title":"Bioconjug Chem"},{"key":"ref=130","first-page":"249","volume":"Vol. 2","author":"Faisca Phillips A.M.M.","year":"2019","unstructured":"Faisca Phillips A.M.M.; Synthesis and Applications of Pharmacologically Relevant Phosphonates and Phosphinates. Organic and Medicinal Chemistry 2019,Vol. 2,249-319","journal-title":"Organic and Medicinal Chemistry"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejmech.2013.05.036","volume":"66","author":"Bhattacharya A.K.","year":"2013","unstructured":"Bhattacharya A.K.; Raut D.S.; Rana K.C.; Polanki I.K.; Khan M.S.; Iram S.; Diversity-oriented synthesis of \u03b1-aminophosphonates: a new class of potential anticancer agents. Eur J Med Chem 2013,66,146-152","journal-title":"Eur J Med Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1016\/j.bmc.2017.07.011","volume":"25","author":"Huang X.","year":"2017","unstructured":"Huang X.; Huang R.; Gou S.; Wang Z.; Liao Z.; Wang H.; Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance. Bioorg Med Chem 2017,25(17),4686-4700","journal-title":"Bioorg Med Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/187231211796904973","volume":"5","author":"Le Broc-Ryckewaert D.","year":"2011","unstructured":"Le Broc-Ryckewaert D.; Pommery N.; Pommery J.; Ghinet A.; Farce A.; Wiart J.F.; Gautret P.; Rigo B.; H\u00e9nichart J.P.; In vitro metabolism of phenstatin: potential pharmacological consequences. Drug Metab Lett 2011,5(3),209-215","journal-title":"Drug Metab Lett"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1582-4934.2003.tb00222.x","volume":"7","author":"Trifan O.C.","year":"2003","unstructured":"Trifan O.C.; Hla T.; Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003,7(3),207-222","journal-title":"J Cell Mol Med"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"Rothwell P.M.","year":"2011","unstructured":"Rothwell P.M.; Fowkes F.G.R.; Belch J.F.F.; Ogawa H.; Warlow C.P.; Meade T.W.; Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011,377(9759),31-41","journal-title":"Lancet"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1734-1140(10)70262-0","volume":"62","author":"Ghosh N.","year":"2010","unstructured":"Ghosh N.; Chaki R.; Mandal V.; Mandal S.C.; COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010,62(2),233-244","journal-title":"Pharmacol Rep"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/anie.201308899","volume":"53","author":"Pathak R.K.","year":"2014","unstructured":"Pathak R.K.; Marrache S.; Choi J.H.; Berding T.B.; Dhar S.; The prodrug platin-A: simultaneous release of cisplatin and aspirin. Angew Chem Int Ed Engl 2014,53(7),1963-1967","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1039\/C4CC00419A","volume":"50","author":"Cheng Q.","year":"2014","unstructured":"Cheng Q.; Shi H.; Wang H.; Min Y.; Wang J.; Liu Y.; The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells. Chem Commun (Camb) 2014,50(56),7427-7430","journal-title":"Chem Commun (Camb)"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1126\/science.337.6101.1471","volume":"337","author":"Kaiser J.","year":"2012","unstructured":"Kaiser J.; Will an aspirin a day keep cancer away? Science 2012,337(6101),1471-1473","journal-title":"Science"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"Algra A.M.","year":"2012","unstructured":"Algra A.M.; Rothwell P.M.; Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012,13(5),518-527","journal-title":"Lancet Oncol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/cmdc.201402074","volume":"9","author":"Neumann W.","year":"2014","unstructured":"Neumann W.; Crews B.C.; Marnett L.J.; Hey-Hawkins E.; Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance. ChemMedChem 2014,9(6),1150-1153","journal-title":"ChemMedChem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/cmdc.201402353","volume":"10","author":"Neumann W.","year":"2015","unstructured":"Neumann W.; Crews B.C.; S\u00e1rosi M.B.; Daniel C.M.; Ghebreselasie K.; Scholz M.S.; Marnett L.J.; Hey-Hawkins E.; Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem 2015,10(1),183-192","journal-title":"ChemMedChem"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bcp.2017.03.004","volume":"135","author":"Chen F.","year":"2017","unstructured":"Chen F.; Qin X.; Xu G.; Gou S.; Jin X.; Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-\u03baB pathways. Biochem Pharmacol 2017,135,50-68","journal-title":"Biochem Pharmacol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1527-3458.2005.tb00266.x","volume":"11","author":"Tai M.C.","year":"2005","unstructured":"Tai M.C.; Tsang S.Y.; Chang L.Y.; Xue H.; Therapeutic potential of wogonin: a naturally occurring flavonoid. CNS Drug Rev 2005,11(2),141-150","journal-title":"CNS Drug Rev"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jinorgbio.2017.07.002","volume":"175","author":"Hu W.","year":"2017","unstructured":"Hu W.; Fang L.; Hua W.; Gou S.; Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance. J Inorg Biochem 2017,175,47-57","journal-title":"J Inorg Biochem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejmech.2017.05.056","volume":"137","author":"Qin X.","year":"2017","unstructured":"Qin X.; Fang L.; Chen F.; Gou S.; Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a \u201cjoint action\u201d mode toward DNA. Eur J Med Chem 2017,137,167-175","journal-title":"Eur J Med Chem"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.1994.12.9.1974","volume":"12","author":"Faguet G.B.","year":"1994","unstructured":"Faguet G.B.; Chronic lymphocytic leukemia: an updated review. J Clin Oncol 1994,12(9),1974-1990","journal-title":"J Clin Oncol"},{"key":"ref=148","first-page":"554","volume":"49","author":"Bank B.B.","year":"1989","unstructured":"Bank B.B.; Kanganis D.; Liebes L.F.; Silber R.; Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes. Cancer Res 1989,49(3),554-559","journal-title":"Cancer Res"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1039\/C8SC00428E","volume":"9","author":"Petruzzella E.","year":"2018","unstructured":"Petruzzella E.; Sirota R.; Solazzo I.; Gandin V.; Gibson D.; Gibson D.; Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chem Sci (Camb) 2018,9(18),4299-4307","journal-title":"Chem Sci (Camb)"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1087057104265040","volume":"9","author":"Kunz-Schughart L.A.","year":"2004","unstructured":"Kunz-Schughart L.A.; Freyer J.P.; Hofstaedter F.; Ebner R.; The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004,9(4),273-285","journal-title":"J Biomol Screen"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"11539","DOI":"10.1002\/anie.201706739","volume":"56","author":"Petruzzella E.","year":"2017","unstructured":"Petruzzella E.; Braude J.P.; Aldrich-Wright J.R.; Gandin V.; Gibson D.; A quadruple-action platinum(IV) prodrug with anticancer activity against KRAS mutated cancer cell lines. Angew Chem Int Ed Engl 2017,56(38),11539-11544","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cmdc.200600211","volume":"2","author":"Fisher D.M.","year":"2007","unstructured":"Fisher D.M.; Bednarski P.J.; Gr\u00fcnert R.; Turner P.; Fenton R.R.; Aldrich-Wright J.R.; Chiral platinum(II) metallointercalators with potent in vitro cytotoxic activity. ChemMedChem 2007,2(4),488-495","journal-title":"ChemMedChem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1039\/C7DT01054K","volume":"46","author":"Harper B.W.J.","year":"2017","unstructured":"Harper B.W.J.; Petruzzella E.; Sirota R.; Faccioli F.F.; Aldrich-Wright J.R.; Gandin V.; Gibson D.; Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline). Dalton Trans 2017,46(21),7005-7019","journal-title":"Dalton Trans"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1021\/ja8081044","volume":"131","author":"Ernst R.J.","year":"2009","unstructured":"Ernst R.J.; Song H.; Barton J.K.; DNA mismatch binding and antiproliferative activity of rhodium metalloinsertors. J Am Chem Soc 2009,131(6),2359-2366","journal-title":"J Am Chem Soc"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1087057110385227","volume":"16","author":"Ansari K.I.","year":"2011","unstructured":"Ansari K.I.; Kasiri S.; Grant J.D.; Mandal S.S.; Fe(III)-salen and salphen complexes induce caspase activation and apoptosis in human cells. J Biomol Screen 2011,16(1),26-35","journal-title":"J Biomol Screen"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1039\/C7CS00332C","volume":"47","author":"Meier-Menches S.M.","year":"2018","unstructured":"Meier-Menches S.M.; Gerner C.; Berger W.; Hartinger C.G.; Keppler B.K.; Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. Chem Soc Rev 2018,47(3),909-928","journal-title":"Chem Soc Rev"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1039\/c1md00075f","volume":"2","author":"Shnyder S.D.","year":"2011","unstructured":"Shnyder S.D.; Fu Y.; Habtemariam A.; van Rijt S.H.; Cooper P.A.; Loadmana P.M.; Sadler P.J.; Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex. MedChemComm 2011,2(7),666-668","journal-title":"MedChemComm"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1021\/jm3017442","volume":"56","author":"Romero-Canel\u00f3n I.","year":"2013","unstructured":"Romero-Canel\u00f3n I.; Salassa L.; Sadler P.J.; The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway. J Med Chem 2013,56(3),1291-1300","journal-title":"J Med Chem"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jorganchem.2006.10.033","volume":"692","author":"Sch\u00e4fer S.","year":"2007","unstructured":"Sch\u00e4fer S.; Sheldrick W.S.; Coligand tuning of the DNA binding properties of half-sandwich organometallic intercalators: Influence of polypyridyl (pp) and monodentate ligands (L= Cl, (NH)CS, (NMe)CS) on the intercalation of (\u03b7-pentamethylcyclopentadienyl)-iridium(III)-dipyrido-quinox-aline and -dipyridophenazine complexes. J Organomet Chem 2007,692(6),1300-1309","journal-title":"J Organomet Chem"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jinorgbio.2009.08.003","volume":"103","author":"Ali Nazif M.","year":"2009","unstructured":"Ali Nazif M.; Bangert J-A.; Ott I.; Gust R.; Stoll R.; Sheldrick W.S.; Dinuclear organoiridium(III) mono- and bis-intercalators with rigid bridging ligands: synthesis, cytotoxicity and DNA binding. J Inorg Biochem 2009,103(10),1405-1414","journal-title":"J Inorg Biochem"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1021\/om500644f","volume":"33","author":"Liu Z.","year":"2014","unstructured":"Liu Z.; Romero-Canel\u00f3n I.; Habtemariam A.; Clarkson G.J.; Sadler P.J.; Potent half-sandwich iridium(III) anticancer complexes containing C\u2227N-chelated and pyridine ligands. Organometallics 2014,33(19),5324-5333","journal-title":"Organometallics"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T11:36:03Z","timestamp":1662550563000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167993\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":161,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2020,1,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666181203141122","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}